Design Therapeutics, Inc. (DSGN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.24-2.38%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Design Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.38
Annual ending 2026-12-31
Revenue	—	117.33M
EPS	—	-1.316
Annual ending 2027-12-31
Revenue	—	204.78M
EPS	—	-1.589

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance clinical development of DT-216P2 for Friedreich ataxia	The company keeps advancing its clinical trial for DT-216P2.	Intact	trial data fails to show safety or clinical benefit next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management reported ongoing RESTORE-FA trial progress with modifications and expects 12-week data in Q1 2027 and a registrational update in Q4 2026. Cash reserves declined from $222.8M in 2026-Q1 to $207.4M in 2026-Q2, supporting continued clinical development. The trajectory shows delivering clinical advancement consistent with stated plans. Delivery assessment Oct 24, 2026
Maintain leadership and governance stability	A supporting condition in Design Therapeutics, Inc.'s published investment case. The stated target is No major unexpected leadership departures in next 4 quarters.	Intact	unexpected loss of key executives or directors	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q1. Management appointed Dr. David Shapiro to the Board to enhance leadership and governance. No further updates in 2026-Q2. This indicates initial action taken to strengthen governance with limited subsequent commentary. Delivery assessment Oct 24, 2026
Manage operating expenses and cash burn	Operating losses and cash burn are high but expected in this phase.	Intact	operating losses or cash burn worsen beyond negative $20M per quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated this priority in 2 of last 2 quarters. R&D expenses rose from $14.4M in 2026-Q1 to $16.4M in 2026-Q2, and net loss increased from $17.6M to $20.2M. Cash reserves declined but remain strong at $207.4M in 2026-Q2, supporting runway into 2029. The trajectory shows ongoing expense management with moderate increases consistent with clinical progress. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.59

$-1.64 → $-1.59 · observed estimates

FY2027 revenue$0.20B

$0.20B → $0.20B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.64	$204,776,000	5 / 7
2026-07-25	$-1.64	$0	7 / 7
2026-07-26	$-1.64	$0	7 / 7
2026-07-27	$-1.64	$204,776,000	5 / 7
2026-07-28	$-1.64	$0	7 / 7
2026-07-29	$-1.64	$0	7 / 7
2026-07-30	$-1.64	$0	7 / 7
2026-07-31	$-1.64	$0	7 / 7
2026-08-01	$-1.64	$204,776,000	5 / 7
2026-08-02	$-1.64	$0	7 / 7
2026-08-03	$-1.64	$0	7 / 7
2026-08-04	$-1.64	$0	7 / 7
2026-08-05	$-1.61	$0	7 / 7
2026-08-06	$-1.58	$204,776,000	5 / 7
2026-08-07	$-1.56	$204,776,000	5 / 7
2026-08-08	$-1.61	$0	7 / 7
2026-08-09	$-1.61	$0	7 / 7
2026-08-10	$-1.56	$204,776,000	5 / 7
2026-08-11	$-1.59	$0	7 / 7
2026-08-12	$-1.59	$0	7 / 7
2026-08-13	$-1.56	$204,776,000	5 / 7
2026-08-14	$-1.56	$204,776,000	5 / 7
2026-08-15	$-1.56	$204,776,000	5 / 7
2026-08-16	$-1.56	$204,776,000	5 / 7
2026-08-17	$-1.56	$204,776,000	5 / 7
2026-08-18	$-1.56	$204,776,000	5 / 7
2026-08-19	$-1.56	$204,776,000	5 / 7
2026-08-20	$-1.56	$204,776,000	5 / 7
2026-08-21	$-1.56	$204,776,000	5 / 7
2026-08-22	$-1.56	$204,776,000	5 / 7
2026-08-23	$-1.56	$204,776,000	5 / 7
2026-08-24	$-1.56	$204,776,000	5 / 7
2026-08-25	$-1.56	$204,776,000	5 / 7
2026-08-26	$-1.56	$204,776,000	5 / 7
2026-08-27	$-1.56	$204,776,000	5 / 7
2026-08-28	$-1.56	$204,776,000	5 / 7
2026-08-29	$-1.56	$204,776,000	5 / 7
2026-08-30	$-1.56	$204,776,000	5 / 7
2026-08-31	$-1.56	$204,776,000	5 / 7
2026-09-01	$-1.56	$204,776,000	5 / 7
2026-09-02	$-1.56	$204,776,000	5 / 7
2026-09-03	$-1.56	$204,776,000	5 / 7
2026-09-04	$-1.56	$204,776,000	5 / 7
2026-09-05	$-1.56	$204,776,000	5 / 7
2026-09-06	$-1.56	$204,776,000	5 / 7
2026-09-07	$-1.56	$204,776,000	5 / 7
2026-09-08	$-1.56	$204,776,000	5 / 7
2026-09-09	$-1.56	$204,776,000	5 / 7
2026-09-10	$-1.56	$204,776,000	5 / 7
2026-09-11	$-1.56	$204,776,000	5 / 7
2026-09-12	$-1.56	$204,776,000	5 / 7
2026-09-13	$-1.56	$204,776,000	5 / 7
2026-09-14	$-1.56	$204,776,000	5 / 7
2026-09-15	$-1.56	$204,776,000	5 / 7
2026-09-16	$-1.56	$204,776,000	5 / 7
2026-09-17	$-1.56	$204,776,000	5 / 7
2026-09-18	$-1.56	$204,776,000	5 / 7
2026-09-19	$-1.56	$204,776,000	5 / 7
2026-09-20	$-1.56	$204,776,000	5 / 7
2026-09-21	$-1.56	$204,776,000	5 / 7
2026-09-22	$-1.56	$204,776,000	5 / 7
2026-09-23	$-1.56	$204,776,000	5 / 7
2026-09-24	$-1.56	$204,776,000	5 / 7
2026-09-25	$-1.56	$204,776,000	5 / 7
2026-09-26	$-1.56	$204,776,000	5 / 7
2026-09-27	$-1.56	$204,776,000	5 / 7
2026-09-28	$-1.56	$204,776,000	5 / 7
2026-09-29	$-1.56	$204,776,000	5 / 7
2026-09-30	$-1.56	$204,776,000	5 / 7
2026-10-01	$-1.56	$204,776,000	5 / 7
2026-10-02	$-1.56	$204,776,000	5 / 7
2026-10-03	$-1.59	$204,776,000	5 / 7
2026-10-04	$-1.59	$204,776,000	5 / 7
2026-10-05	$-1.59	$204,776,000	6 / 8
2026-10-06	$-1.59	$204,776,000	6 / 8
2026-10-07	$-1.59	$204,776,000	6 / 8
2026-10-08	$-1.59	$204,776,000	6 / 8
2026-10-09	$-1.59	$204,776,000	6 / 8
2026-10-10	$-1.59	$204,776,000	6 / 8
2026-10-11	$-1.59	$204,776,000	6 / 8
2026-10-12	$-1.59	$204,776,000	6 / 8
2026-10-13	$-1.59	$204,776,000	6 / 8
2026-10-14	$-1.59	$204,776,000	6 / 8
2026-10-15	$-1.59	$204,776,000	6 / 8
2026-10-16	$-1.59	$204,776,000	6 / 8
2026-10-17	$-1.59	$204,776,000	6 / 8
2026-10-18	$-1.59	$204,776,000	6 / 8
2026-10-19	$-1.59	$204,776,000	6 / 8
2026-10-20	$-1.59	$204,776,000	6 / 8
2026-10-21	$-1.59	$204,776,000	6 / 8
2026-10-22	$-1.59	$204,776,000	6 / 8
2026-10-23	$-1.59	$204,776,000	6 / 8
2026-10-24	$-1.59	$204,776,000	6 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	7	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wells FargoOct 2

$26.00New observation · no comparable prior

$0$14.30$28.60

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance clinical development of DT-216P2 for Friedreich ataxiaDirect metric needs a verified mapping
Maintain leadership and governance stabilityDirect metric needs a verified mapping
Manage operating expenses and cash burnDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-39.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Design Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage biotech exposure, not an established earnings compounder. The thesis is in a watch state: management is advancing its lead program, but the evidence snapshot has low confidence and the business remains loss-making.

What's priced into Design Therapeutics, Inc.

The evidence does not include a valuation measure or a clear account of market expectations, so whether DSGN is cheap, fair, or expensive versus peers is unclear. Recent earnings beats have had a muted price reaction, while weak performance relative to its industry cohort suggests the market response has not removed the main concerns.

What the fundamentals likely do

Near term, management expects a registrational update in Q4 2026 and 12-week trial data in Q1 2027, while cash reserves support a stated runway into 2029. However, R&D expense and net loss increased in Q2, and the next report carries elevated miss risk; the recent earnings beats offer some counterweight.

What Design Therapeutics, Inc. hinges on

The multi-year thesis hinges on continued progress in the RESTORE-FA trial and whether upcoming updates strengthen the case for DT-216P2. Near-term conditions could also be affected by weakening jobs data or changes in healthcare-sector momentum, including results and guidance from VRTX, REGN, and MRNA.